Literature DB >> 9593578

Intracellular and serum stability of liposomal 2',3'-dideoxycytidine. Effect of lipid composition.

B Makabi-Panzu1, P Gourde, A Désormeaux, M G Bergeron.   

Abstract

The serum and intracellular stability of 2',3'-dideoxycytidine (ddC) encapsulated in liposomes having different physicochemical properties have been investigated. Results showed that the presence of cholesterol in the lipid composition of liposomes resulted in an increased leakage of ddC when incubated in 80% serum at 37 degrees C. The length of the hydrocarbon chains of the phosphatidylcholine component in cholesterol-containing liposomes did not induce major modifications in both the efficiency of encapsulation and retention of the antiviral agent. The uptake and intracellular stability of the different liposomal formulations have also been evaluated as a function of drug concentration in RAW 264.7 macrophages. For all liposomal formulations tested, an enhanced uptake of liposome-encapsulated ddC by macrophages was observed when the liposomal drug concentration was increased. In addition, the anionic character of liposomes seemed to be an important factor to obtain a high intracellular uptake of ddC. The drug release from liposomal ddC-loaded macrophages has also been evaluated in serum-free medium. Liposomes having long saturated fatty acyl phospholipids and containing 50% (molar ratio) of cholesterol displayed the best stability in the intramacrophagic compartments at all liposomal ddC concentrations used. On the other hand, although the leakage of ddC from liposomes sterically stabilized with polyethyleneglycol chains was similar to that of other cholesterol-containing liposomes, the antiviral agent was readily released from cells for all concentrations of liposomal ddC tested. In conclusion, these results show that the serum stability does not necessarily reflect the intracellular stability, and suggest that some lipid components such as cholesterol can modulate the liposomal stability of drugs such as ddC in response to the conditions of the environment, the properties of the drug used and the nature of interactions between liposomes and cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593578

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  5 in total

Review 1.  Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS.

Authors:  Jingwei Shao; John C Kraft; Bowen Li; Jesse Yu; Jennifer Freeling; Josefin Koehn; Rodney Jy Ho
Journal:  Nanomedicine (Lond)       Date:  2016-02-19       Impact factor: 5.307

2.  Liposomes as Carriers for the Delivery of Efavirenz in Combination with Glutathione-An Approach to Combat Opportunistic Infections.

Authors:  Vanaja Kenchappa; Ruoqiong Cao; Vishwanath Venketaraman; Guru V Betageri
Journal:  Appl Sci (Basel)       Date:  2022-01-29       Impact factor: 2.838

Review 3.  Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs.

Authors:  Simi Gunaseelan; Krishnan Gunaseelan; Manjeet Deshmukh; Xiaoping Zhang; Patrick J Sinko
Journal:  Adv Drug Deliv Rev       Date:  2009-11-24       Impact factor: 15.470

Review 4.  Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS.

Authors:  Madhavan Nair; Rahul Dev Jayant; Ajeet Kaushik; Vidya Sagar
Journal:  Adv Drug Deliv Rev       Date:  2016-03-02       Impact factor: 15.470

5.  Development of a liposomal nanodelivery system for nevirapine.

Authors:  Lakshmi N Ramana; Swaminathan Sethuraman; Udaykumar Ranga; Uma M Krishnan
Journal:  J Biomed Sci       Date:  2010-07-13       Impact factor: 8.410

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.